Quick Answer
Kiniksa Pharmaceuticals International, plc reported Total Assets of $763.63 million for the year ending 2025.
- Kiniksa Pharmaceuticals International, plc showed an increase of +31.5% in Total Assets from 2024 to 2025.
- This data is from Kiniksa Pharmaceuticals International, plc's annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $365.13 million | Q3 2018: $347.10 million | Q1 2019: $346.16 million | Q2 2019: $308.14 million | Q3 2019: $281.81 million | Q1 2020: $226.11 million | Q2 2020: $271.44 million | Q3 2020: $384.41 million | Q1 2021: $311.16 million | Q2 2021: $279.21 million | Q3 2021: $252.86 million | Q1 2022: $230.97 million | Q2 2022: $210.58 million | Q3 2022: $459.95 million | Q1 2023: $442.86 million | Q2 2023: $484.33 million | Q3 2023: $483.06 million | Q1 2024: $519.67 million | Q2 2024: $542.43 million | Q3 2024: $555.30 million | Q1 2025: $599.33 million | Q2 2025: $661.15 million | Q3 2025: $712.33 million.
- Over the full 9 years of available data (2017 to 2025), Kiniksa Pharmaceuticals International, plc's Total Assets has grown by 1,507.9%.
- Historical annual values: Fiscal year 2025: $763.63 million | Fiscal year 2024: $580.55 million | Fiscal year 2023: $526.32 million | Fiscal year 2022: $459.67 million | Fiscal year 2021: $232.80 million | Fiscal year 2020: $349.46 million | Fiscal year 2019: $254.53 million | Fiscal year 2018: $321.97 million | Fiscal year 2017: $47.49 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: